Want to join the conversation?
$VRSN 2Q15 Call: 2015 Guidance: Revenue of $1.045-1.055Bil represents annual growth rate of 3.5-4.5%. This range was narrowed from $1.043-$1.057Bil given on 1Q15. Non-GAAP GM, at least 80%; operating margin, 60-62%; interest expense and non-operating income, net to be an expense of $104-110MM. 2015 CapEx to be $40-50MM.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.